Back to top
more

iTeos Therapeutics (ITOS)

(Delayed Data from NSDQ)

$10.13 USD

10.13
1,226,787

+0.02 (0.20%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $10.12 -0.01 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down

by Zacks Equity Research

Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.

Zacks Equity Research

ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Zacks Equity Research

Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -62.42% and -68.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

by Zacks Equity Research

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

Zacks Equity Research

Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

Zacks Equity Research

Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

by Zacks Equity Research

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.